Sanofi/Regeneron's Zaltrap fails in third oncology indication - prostate cancer
This article was originally published in Scrip
Sanofi and Regeneron's Zaltrap (aflibercept) has failed to meet the primary endpoint in the Phase III VENICE trial for the first-line treatment of metastatic androgen-independent prostate cancer, top-line results show. This is the third oncology indication in which the drug has failed.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.